Characteristics of HIV-positive men who have sex with men (MSM) in San Francisco in the Options cohort at the time of first ACASI, 2009–2010.

<p>Characteristics of HIV-positive men who have sex with men (MSM) in San Francisco in the Options cohort at the time of first ACASI, 2009–2010.</p

Mean number of partners of various types per 3 months since HIV diagnosis among HIV-positive MSM in San Francisco, 2009–2010.

<p>An immediate drop in the total number of male partners in the first year of infection was followed by increases in number of partners over the following 3–4 years. The trend was similar for potentially serodiscordand partners (PDPs) although they comprised only 1/3 to 1/2 of total partnerships. However, unprotected anal intercourse (UAI) with PDPs occurred in far fewer partnerships throughout the follow-up period. Partnerships in which the HIV-positive participant was the insertive partner during unprotected anal intercourse (uIAI) accounted for fewer than 10% of all partnerships and in very few of those partnerships did the participant have sufficient plasma viral load (VL >500 copies/ml) to present a significant transmission risk.</p

Estimated mean number of sexual partners per prior 3-month period and 95% confidence intervals [CI] for each sexual behavior variable of interest among MSM in Options/San Francisco, 2009–2010.

∧<p>Number of participants who contribute to each time point varies because this was not a strictly longitudinal cohort study. All participants started contributing data in 2009, and were at various times since diagnosis when they completed their ACASIs.</p>∧∧<p>PDP = potentially discordant partners (HIV-negative or unknown-status partners).</p>*<p>UAI = unprotected anal intercourse.</p>**<p>uIAI = unprotected insertive anal intercourse.</p>***<p>For participants with plasma viral load <500 copies/ml, number of PDP with whom uIAI occurred was set to 0.</p

Subject HLA information of responders.

<p>* Four digit HLA typing where HLA alleles matched between source and recipient</p><p>** Source transmitted HIV-1 virus to two different recipients</p><p>Subject HLA information of responders.</p

Annual prevalence of transmitted HIV-1 drug resistance in 372 patients with acute/early HIV, 2002-2009.

<p>Prevalence (dot) and 95% confidence interval (vertical line) of overall transmitted drug resistance <i>(A),</i> NRTI resistance <i>(B),</i> NNRTI resistance <i>(C),</i> and PI resistance <i>(D).</i> TDR, transmitted drug resistance; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</p